Market closed
BeyondSpring/$BYSI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BeyondSpring
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
Ticker
$BYSI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
36
Website
BeyondSpring Metrics
BasicAdvanced
$70M
Market cap
-
P/E ratio
-$0.40
EPS
0.26
Beta
-
Dividend rate
Price and volume
Market cap
$70M
Beta
0.26
52-week high
$4.00
52-week low
$0.78
Average daily volume
22K
Financial strength
Current ratio
1.822
Quick ratio
1.754
Long term debt to equity
-11.532
Total debt to equity
-14.029
Management effectiveness
Return on assets (TTM)
-39.64%
Return on equity (TTM)
78.43%
Valuation
Price to revenue (TTM)
36.214
Price to book
-2.32
Price to tangible book (TTM)
-2.32
Growth
Revenue change (TTM)
21.03%
Earnings per share change (TTM)
-43.40%
3-year revenue growth (CAGR)
29.89%
3-year earnings per share growth (CAGR)
-40.82%
What the Analysts think about BeyondSpring
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BeyondSpring stock.
BeyondSpring Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BeyondSpring Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BeyondSpring News
AllArticlesVideos
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
GlobeNewsWire·2 weeks ago
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
GlobeNewsWire·2 months ago
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BeyondSpring stock?
BeyondSpring (BYSI) has a market cap of $70M as of November 23, 2024.
What is the P/E ratio for BeyondSpring stock?
The price to earnings (P/E) ratio for BeyondSpring (BYSI) stock is 0 as of November 23, 2024.
Does BeyondSpring stock pay dividends?
No, BeyondSpring (BYSI) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next BeyondSpring dividend payment date?
BeyondSpring (BYSI) stock does not pay dividends to its shareholders.
What is the beta indicator for BeyondSpring?
BeyondSpring (BYSI) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.